Thyme Care Raises $125M, Forms Thyme Companies
Thyme Care Raises $125M, Forms Thyme Companies
Anonymous
Key Points
1
Thyme Care will reorganize under a new parent entity, Thyme Companies, with co‑founder Robin Shah named executive chairman of the parent and Bobby Green, M.D., serving as president, while Thyme Care's current CEO Brad Diephuis, M.D., remains at the helm of the operating company.
2
The financing rounds used convertible preferred stock for Thyme Care's Series E, a structure that signals a pathway to equity upside for investors while maintaining control dynamics for the company.
3
Dan Mendelson, CEO of Morgan Health, framed Thyme Care’s model as a correction to a long‑standing problem where cancer patients must coordinate care themselves and often incur higher costs, underscoring the drive to improve care while lowering overall costs.
4
In addition to Morgan Health, the Series E drew a broad group of investors beyond Humana and CVS Health Ventures, including AlleyCorp, HealthQuest Capital, Foresite Capital, Concord Health Partners, Frist Cressey Ventures, Town Hall Ventures and a16z Bio + Health.
Thyme Care, a Nashville-based oncology company, has raised over $125 million in Series E funding, pushing its valuation above $2 billion MedCity News. The round was led by Morgan Health and includes backing from Humana, CVS Health Ventures, and a roster of health-focused investors. The financing supports Thyme Care's expansion and the creation of Thyme Companies, a new parent entity designed to build a portfolio of oncology businesses.
Thyme Care manages more than $7 billion in oncology spending and serves 10.5 million lives across all 50 states Pulse2. The company's value-based care model aligns financial incentives with patient outcomes, aiming to reduce costs and improve care coordination. The financing signals strong investor confidence in cancer care startups that promise to lower overall costs while improving access to treatment.
A $2 Billion Valuation Reflects Market Momentum
Thyme Care's Series E round values the oncology company at more than $2 billion Archynetys. Led by Morgan Health with participation from Humana and CVS Health Ventures, the funding brings together strategic payers and institutional investors. The round also includes backing from AlleyCorp, HealthQuest Capital, Foresite Capital, Concord Health Partners, Frist Cressey Ventures, Town Hall Ventures, and a16z Bio + Health Market Screener.
New Parent Company Signals Portfolio Expansion Plans
Thyme Care will reorganize under a new parent entity called Thyme Companies Pulse2. Co-founder Robin Shah moves to executive chairman of the parent, while Bobby Green, M.D., becomes president. Brad Diephuis, M.D., remains CEO of Thyme Care's operating company. The restructuring sets the stage for launching new oncology businesses addressing biosimilars adoption and clinical-trial enrollment later this year.
Care Coordination Model Attracts Strategic Payers
Thyme Care's model shifts financial risk to the healthcare provider, aligning incentives to reduce costs and improve care. Dan Mendelson, CEO of Morgan Health, framed the approach as fixing a long-standing problem where cancer patients must coordinate their own care and often face higher costs MedCity News. By bundling care and ensuring accountability, Thyme Care claims to lower overall spending while improving patient experience and access to treatment.
Path to Profitability Demonstrates Unit Economics
Thyme Care reports achieving positive free cash flow under its care-coordination approach Pulse2. Managing $7 billion in oncology spend across 10.5 million lives demonstrates the company's scale. The financing round used convertible preferred stock, signaling a pathway to equity upside for investors while maintaining the company's control structure as it scales operations.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
10
Articles
4
Reach
14
A
AnonymousAuthor
